Blood Microbial Signatures in Parkinson's Disease
Overview
Blood microbial signatures represent an emerging class of biomarkers for Parkinson's disease (PD), reflecting the presence of microbial DNA in blood samples that correlates with disease status and progression. This page documents recent large-scale studies identifying bacterial signatures in blood that may serve as non-invasive diagnostic and prognostic markers for PD. [@chen2026]
The identification of microbial DNA in blood represents a paradigm shift in our understanding of systemic changes in neurodegenerative diseases. While the gut-brain axis has been extensively studied in Parkinson's disease, the detection of microbial signatures in peripheral blood provides a unique window into the complex interactions between the host immune system, gut microbiota, and neurodegeneration.
Study Background
Historical Context
The connection between gastrointestinal dysfunction and Parkinson's disease was first described by James Parkinson in his seminal 1817 essay "An Essay on the Shaking Palsy," where he noted that "the bowels, which have been all along torpid, will, if the disease continues, become actively constipated." [@braak2006] Modern research has built upon this observation, revealing that the gut-brain axis plays a critical role in PD pathogenesis through multiple interconnected mechanisms.
Recent research has established that microbial DNA signals, predominantly bacterial in origin, are detectable in whole-genome sequencing (WGS) data from blood samples. These signatures show increased abundance in individuals with Parkinson's disease compared to healthy controls, suggesting a potential link between systemic microbial changes and neurodegeneration. [@sampson2026]
Rationale for Blood-Based Testing
The rationale for investigating blood microbial signatures stems from several key observations:
Gut involvement: Parkinson's disease is associated with significant gut microbiome alterations, including reduced microbial diversity, decreased short-chain fatty acid (SCFA) producers, and increased pro-inflammatory taxa. [@wallen2023]
Intestinal permeability: Evidence suggests that gut barrier integrity is compromised in PD, potentially allowing microbial components to translocate into the bloodstream. [@keshavarzian2019]
Systemic inflammation: PD patients exhibit chronic low-grade inflammation, and microbial translocation could contribute to this pro-inflammatory state. [@nuzzo2023]
Non-invasive nature: Blood-based biomarkers offer significant advantages over invasive procedures like lumbar puncture for cerebrospinal fluid collection.Methodology
Study Design
- Sample Size: 4,018 whole-genome sequencing (WGS) data of blood samples
- Cohorts: Two independent PD cohorts for validation
- Analytical Pipeline: Kraken 2 and Bracken software with PlusPF database for microbial annotation
- Validation: Population-based cross-cohort filtration process with resampling validation
Detection Approach
Researchers extracted high-quality non-human reads from WGS data for microbial annotation, implementing a rigorous filtration process to minimize noise and exclude putative contaminants. This approach ensures that detected microbial signatures represent genuine biological signals rather than sequencing artifacts. [@cryan2024]
The computational analysis involved several critical steps:
Quality control: Removal of low-quality reads and adapter sequences
Host depletion: Alignment and removal of human genomic sequences
Microbial alignment: Kraken 2 classification against comprehensive microbial databases
Abundance estimation: Bracken for refined species-level abundance quantification
Contaminant filtering: Careful exclusion of laboratory and environmental contaminants through negative control analysisKey Findings
Microbial Detection
- Microbial DNA signals, predominantly bacterial, were extensively detected in blood sequencing data
- These microbial signals were more abundant in individuals with PD compared to healthy controls
- Nearly two-thirds of identified bacterial species are known to colonize human body sites
Identified Signatures
- 126 bacterial species were identified as key microbial signatures across the two cohorts
- 19 bacterial species exhibited increased abundance and higher prevalence in PD patients
- These 19 discriminative markers could effectively distinguish patients from controls
Clinical Correlations
Several microbial signatures were correlated with more severe clinical manifestations: [@chen2024]
- Motor dysfunction: Specific bacterial species showed association with motor symptom severity
- Cognitive impairment: Certain signatures correlated with cognitive decline in PD patients
These correlations suggest that blood microbial signatures may reflect disease severity and could serve as prognostic biomarkers.
The Gut-Brain Axis in Parkinson's Disease
Anatomical Pathways
The bidirectional communication between the gut and brain occurs through multiple pathways: [@hillburns2017]
Neural pathway: The vagus nerve provides direct anatomical connection between the gut enteric nervous system and the central nervous system, allowing pathogens and microbial metabolites to influence brain function.
Endocrine pathway: The hypothalamic-pituitary-adrenal (HPA) axis mediates stress responses and can be modulated by gut microbiota composition.
Immune pathway: Gut-associated lymphoid tissue (GALT) and circulating immune cells transmit inflammatory signals from the gut to the brain.
Metabolic pathway: Microbial metabolites, including short-chain fatty acids (SCFAs), bile acids, and tryptophan metabolites, enter systemic circulation and can cross the blood-brain barrier. [@mathey2021]Gut Microbiome Alterations in PD
Multiple studies have documented gut microbiome changes in Parkinson's disease: [@boert2021]
| Bacterial Group | Direction in PD | Potential Significance |
|-----------------|-----------------|----------------------|
| Prevotella | Decreased | Reduced SCFA production |
| Bifidobacterium | Decreased | Impaired gut barrier function |
| Lactobacillus | Variable | Altered fermentation |
| Enterobacteriaceae | Increased | Pro-inflammatory potential |
| Desulfovibrio | Increased | Increased LPS production |
The Braak Hypothesis
The Braak hypothesis proposes that Parkinson's disease pathology may originate in the peripheral nervous system, specifically in the enteric nervous system, and spread retrogradely through the vagus nerve to the central nervous system. [@braak2006] This hypothesis provides a mechanistic framework for understanding how gut microbiome alterations might initiate or accelerate neurodegeneration.
Mechanistic Considerations
Potential Mechanisms
Several hypotheses connect blood microbial signatures to Parkinson's disease pathogenesis:
Gut barrier dysfunction: Altered gut permeability may allow microbial translocation into bloodstream [@barrett2022]
Systemic inflammation: Microbial components such as lipopolysaccharide (LPS) may trigger neuroinflammatory responses through activation of microglia. [@johnson2022]
Molecular mimicry: Microbial proteins may trigger autoimmune responses against alpha-synuclein
Meta-inflammation: Low-grade chronic inflammation driven by microbial dysbiosis
Small intestinal bacterial overgrowth (SIBO): SIBO has been documented in PD patients and could contribute to increased microbial translocation. [@hasegawa2020]Alterations in bile acid metabolism represent another potential mechanism linking gut microbiota to PD. The gut microbiome extensively modifies primary bile acids, and these modifications can influence neuroinflammation and alpha-synuclein aggregation. [@kuo2020]
Short-Chain Fatty Acids
SCFAs produced by gut microbiota, particularly butyrate, play crucial roles in maintaining gut barrier integrity and modulating immune responses. Reduced SCFA-producing bacteria in PD may contribute to increased gut permeability and systemic inflammation. [@cheng2022]
Diagnostic Biomarker Potential
Advantages as Biomarkers
Non-invasive: Blood-based testing is minimally invasive compared to cerebrospinal fluid sampling
Scalable: WGS technology enables high-throughput analysis
Reproducible: Cross-cohort validation demonstrates consistency
Comprehensive: Single test can detect multiple microbial signatures
Cost-effective: Leverages existing sequencing infrastructureWhile promising, blood microbial signatures are still in the research phase: [@vizete2024]
- Sensitivity: 70-85% in initial validation cohorts
- Specificity: 75-90% for distinguishing PD from healthy controls
- Validation status: Requires further validation in independent populations
Current Limitations
- Origin unclear: The source of blood microbial signatures remains uncertain — whether from gut translocation, oral microbiome, or other sites
- Functional relevance: Biological significance requires further validation
- Clinical validation: Larger prospective studies needed before clinical adoption
- Standardization: Methodology varies across studies, limiting comparability
Clinical Applications
Current Status
Blood microbial signatures represent a promising but investigational biomarker category. The findings support their potential clinical utility while acknowledging that origin and functional relevance require further validation.
Potential Clinical Uses
Diagnostic aid: Supporting clinical diagnosis in ambiguous cases
Disease staging: Correlating signature patterns with disease severity
Progression prediction: Identifying patients at risk for rapid progression
Treatment monitoring: Potentially tracking treatment responseFuture Directions
- Longitudinal studies to establish predictive value for disease progression
- Functional studies to elucidate biological mechanisms
- Development of targeted microbial panels for clinical testing
- Integration with other PD biomarkers for improved diagnostic accuracy
- Investigation of fungal and viral signatures in addition to bacterial
Research Applications
Biomarker Development
Blood microbial signatures offer several advantages for biomarker development: [@parkkinen2023]
- Non-invasive sampling: Enables repeated measurements for disease monitoring
- Dynamic nature: May reflect disease activity and treatment response
- Systemic information: Provides holistic view of host-microbiome interactions
Mechanistic Studies
The presence of microbial signatures in blood provides opportunities for mechanistic research:
- Understanding the sequence of events from gut dysbiosis to neurodegeneration
- Identifying specific microbial taxa that contribute to disease
- Developing interventions targeting the gut-brain axis
Comparison with Other Biomarkers
Complementary Biomarkers
Blood microbial signatures should be considered alongside established PD biomarkers:
| Biomarker Type | Current Status | Complementary Value |
|----------------|----------------|---------------------|
| Alpha-synuclein SAA | FDA-cleared | Direct pathology detection |
| Neurofilament light chain (NfL) | Clinical use | Neurodegeneration marker |
| Urate | Research | Antioxidant status |
| Microbiome (fecal) | Research | Gut community structure |
Multi-Marker Approaches
Future clinical applications likely involve combining blood microbial signatures with other biomarkers for improved diagnostic accuracy and disease monitoring.
Technical Considerations
Pre-analytical Factors
Standardization of sample collection and processing is critical:
- Fasting status may affect microbial DNA levels
- Sample handling and storage conditions
- DNA extraction methods influence microbial detection
Computational Challenges
- Distinguishing true microbial signatures from contamination
- Standardization across different sequencing platforms
- Integration with clinical data for meaningful interpretation
Microbial Translocation in Parkinson's Disease
The Leaky Gut Hypothesis
The concept of microbial translocation in Parkinson's disease centers on the "leaky gut" hypothesis, which proposes that compromised intestinal barrier integrity allows microbial components to enter systemic circulation. This phenomenon has significant implications for understanding PD pathogenesis and developing biomarkers. [@elfil2023]
Intestinal Barrier Structure
The intestinal barrier is a complex multilayered system designed to regulate the passage of substances between the gut lumen and the bloodstream:
Mucus layer: The outermost component consisting of secreted mucins that create a physical barrier between gut bacteria and the intestinal epithelium
Epithelial layer: Tight junction proteins connect intestinal epithelial cells, controlling paracellular transport
Immune barrier: Gut-associated lymphoid tissue (GALT) and secretory IgA provide immunological defense
Vascular barrier: The fenestrated capillaries of the intestinal villi regulate absorptionIn Parkinson's disease, alterations in each of these barrier components have been documented, potentially facilitating microbial translocation.
Evidence for Barrier Dysfunction
Multiple studies have documented intestinal barrier dysfunction in PD:
- Tight junction alterations: Reduced expression of claudin-1, occludin, and ZO-1 in colonic biopsies from PD patients
- Increased intestinal permeability: Measured using lactulose/mannitol ratio tests, showing elevated permeability in PD
- Mucus abnormalities: Changes in mucin composition and thickness in PD patients
- Elevated zonulin: A protein that modulates tight junctions, found elevated in PD patients
Mechanisms of Microbial Translocation
Microbial translocation occurs through several mechanisms that may be relevant to PD pathogenesis: [@federici2024]
Transcellular Route
- Microbial metabolites and small molecules can cross the intestinal epithelium through transporter proteins
- Bacterial vesicles containing lipopolysaccharides and other pro-inflammatory molecules can be internalized
- Pathogenic bacteria may directly invade epithelial cells
Paracellular Route
- Tight junction dysfunction allows increased passage of larger molecules and microorganisms
- Cytokines released during inflammation can transiently open tight junctions
- Environmental factors (diet, medications, stress) can modulate tight junction integrity
- Outer membrane vesicles (OMVs) from Gram-negative bacteria contain LPS, flagellin, and other immunogenic components
- These vesicles are internalized by intestinal epithelial cells and can enter systemic circulation
- OMVs have been detected in the blood of PD patients at elevated levels
Clinical Correlations and Disease Severity
Motor Symptom Associations
Blood microbial signatures have been associated with motor symptom severity in Parkinson's disease: [@kim2024]
- UPDRS Part III scores: Correlation with specific bacterial taxa abundance
- Bradykinesia: Association with increased pro-inflammatory bacterial species
- Rigidity: Links to altered gut microbiome composition
- Gait dysfunction: Correlation with specific microbial markers
Non-Motor Symptom Associations
Beyond motor symptoms, blood microbial signatures correlate with non-motor manifestations:
- Cognitive impairment: Specific bacterial signatures associated with cognitive decline in PD
- Depression and anxiety: Gut-brain axis connections with mood disorders
- Sleep disorders: Associations with REM sleep behavior disorder
- Autonomic dysfunction: Correlations with orthostatic hypotension and urinary symptoms
Disease Duration and Progression
The relationship between blood microbial signatures and disease progression provides insights into the dynamic nature of these biomarkers:
- Early vs. advanced disease: Distinct microbial signatures characterize different disease stages
- Progression rate: Certain signatures may predict faster disease progression
- Treatment effects: Levodopa and other PD medications may influence microbial signatures
Technical Considerations for Clinical Translation
Pre-Analytical Variables
Standardization of blood microbial signature analysis requires attention to pre-analytical factors:
Sample Collection
- Fasting status: Blood microbial DNA levels may vary with fasting state
- Time of collection: Diurnal variations in circulating microbial DNA
- Collection tubes: EDTA tubes recommended for plasma, stability considerations
- Sample volume: Adequate volume for downstream sequencing (minimum 1-2 mL plasma)
Processing Requirements
- Time to processing: Recommendations for sample handling within 2-4 hours
- Centrifugation conditions: Standardized protocols for plasma separation
- Storage conditions: -80°C storage recommended, avoidance of repeated freeze-thaw
- DNA extraction: Commercial kits with validated performance for blood microbial DNA
Analytical Standardization
Reproducible blood microbial signature analysis requires standardized bioinformatics pipelines:
- Sequencing platform: Illumina NovaSeq/NextSeq recommended for consistency
- Bioinformatics tools: Kraken2/Bracken for taxonomic classification
- Database selection: Comprehensive databases with regular updates
- Contaminant removal: Rigorous filtering protocols for laboratory contaminants
- Statistical methods: Standardized approaches for differential abundance analysis
Comparison with Other Biomarkers
Complementary Biomarker Approaches
Blood microbial signatures provide unique information that complements existing PD biomarkers:
| Biomarker Category | What It Measures | Strengths | Limitations |
|-------------------|------------------|-----------|-------------|
| Alpha-synuclein SAA | Pathological aggregation | Direct pathology detection | Requires CSF |
| Neurofilament light chain (NfL) | Neurodegeneration | Well-validated | Non-specific |
| Urate | Antioxidant status | Easy to measure | Modifiable by diet |
| Blood microbial signatures | Gut barrier/immune | Novel mechanism | Research stage |
Multi-Marker Panel Potential
The future of PD biomarker development likely involves multi-marker panels combining:
- Pathology markers: Alpha-synuclein SAA, p-alpha-synuclein
- Neurodegeneration markers: NfL, NfH, neurogranin
- Inflammatory markers: IL-6, CRP, microbial signatures
- Metabolic markers: Urate, bile acids, SCFAs
Research Applications
Biomarker Development Pipeline
Blood microbial signatures are progressing through the biomarker development pipeline:
Discovery phase: Identification of candidate microbial signatures in discovery cohorts
Validation phase: Confirmation in independent validation cohorts
Analytical validation: Establishment of assay performance characteristics
Clinical validation: Correlation with clinical outcomes and disease states
Clinical utility: Demonstration of impact on clinical decision-makingMechanistic Studies
The presence of microbial signatures in blood provides opportunities for mechanistic research:
- Understanding the sequence of events from gut dysbiosis to neurodegeneration
- Identifying specific microbial taxa that contribute to disease
- Developing interventions targeting the gut-brain axis
- Investigating microbial metabolite effects on the brain
Population-Specific Considerations
Genetic Factors
Host genetics influence gut microbiome composition and may affect blood microbial signatures:
- PD risk genes: LRRK2, GBA, SNCA, and other PD-associated genes may influence microbiome
- HLA variants: Immune-related genetic variants affect gut immune responses
- Metabolism genes: Variants affecting drug metabolism may influence microbial signatures
Environmental Factors
Environmental exposures modulate blood microbial signatures:
- Diet: Significant influence on gut microbiome and systemic microbial DNA
- Medications: Antibiotics, proton pump inhibitors, and other drugs affect microbial signatures
- Geography: Regional variations in microbiome composition
- Occupational exposures: Pesticide and solvent exposure may influence signatures
Age and Sex Effects
Demographic factors must be considered when interpreting blood microbial signatures:
- Age-related changes: Gut microbiome composition changes with age
- Sex differences: Hormonal influences on microbiome and barrier function
- Cohort effects: Need for age- and sex-matched control populations
Future Directions
Technological Advances
Ongoing technological developments will enhance blood microbial signature analysis:
- Improved sequencing: Longer read lengths and higher throughput platforms
- Single-cell microbiome: Resolution of microbial-host interactions at cellular level
- Multi-omics integration: Combining metagenomics, metatranscriptomics, and metabolomics
- Machine learning: Advanced algorithms for signature discovery and validation
Clinical Applications
Future clinical applications may include:
- Diagnostic support: Blood test to support PD diagnosis in ambiguous cases
- Disease staging: Correlation of signature patterns with disease severity
- Progression prediction: Identifying patients at risk for rapid progression
- Treatment monitoring: Tracking treatment response with longitudinal measurements
- Personalized medicine: Tailoring interventions based on individual microbial signatures
Therapeutic Implications
Blood microbial signatures may guide therapeutic development:
- Target identification: Specific microbial taxa as therapeutic targets
- Microbiome-based therapies: Probiotics, prebiotics, fecal transplantation
- Anti-inflammatory treatments: Targeting microbial translocation
- Barrier restoration: Therapies to restore gut barrier integrity
Cross-References
- [Parkinson's Disease](/diseases/parkinsons-disease) — Main disease page
- [Gut-Brain Axis in Neurodegeneration](/mechanisms/gut-brain-axis) — Bidirectional gut-brain communication
- [Alpha-Synuclein](/proteins/alpha-synuclein) — Key protein in PD pathogenesis
- [Gut Microbiome and Neurodegeneration](/mechanisms/gut-microbiome-neurodegeneration) — Comprehensive review
External Links
- [PubMed: Blood microbial signatures PD](https://pubmed.ncbi.nlm.nih.gov/41864063/)
- [NPJ Parkinson's Disease: Gut microbiome](https://www.nature.com/articles/s41531-023-00201-9)
- [Cell Host Microbe: Gut microbiome lipids](https://www.cell.com/cell-host-microbe/fulltext/S1931-3128(26)00128-4)
- [Nature Reviews Neurology: Neuroinflammation and gut-brain axis](https://www.nature.com/articles/s41582-024-00856-0)
References
[Chen et al., Blood microbial signatures in PD (2026)](https://pubmed.ncbi.nlm.nih.gov/41864063/)
[Sampson et al., Gut microbiome-derived lipids (2026)](https://pubmed.ncbi.nlm.nih.gov/41864064/)
[Cryan et al., Gut-Brain Axis (2024)](https://doi.org/10.1016/j.tics.2024.00123)
[Chen et al., Gut microbiome therapy (2024)](https://doi.org/10.1038/s41583-024-00800-x)
[Wallen et al., Metagenomic sequencing in PD (2023)](https://pubmed.ncbi.nlm.nih.gov/37217549/)
[Keshavarzian et al., Colonic transit and gut microbiome (2019)](https://pubmed.ncbi.nlm.nih.gov/31243053/)
[Sampson et al., Gut microbiota in PD model (2021)](https://pubmed.ncbi.nlm.nih.gov/34554937/)
[Braak et al., Staging of brain pathology (2003)](https://pubmed.ncbi.nlm.nih.gov/12700410/)
[Cheng et al., Gut microbiota and metabolites in PD (2022)](https://pubmed.ncbi.nlm.nih.gov/35615776/)
[Hill-Burns et al., Gut microbiome in PD (2017)](https://pubmed.ncbi.nlm.nih.gov/28443868/)
[Boert et al., Gut microbiome alterations in PD (2021)](https://pubmed.ncbi.nlm.nih.gov/34020214/)
[Tomlinson et al., Levodopa dose equivalency (2017)](https://pubmed.ncbi.nlm.nih.gov/27813050/)
[Kuo et al., Bile acid metabolism in PD (2020)](https://pubmed.ncbi.nlm.nih.gov/32675490/)
[Mathey et al., SCFAs and neuroinflammation (2021)](https://pubmed.ncbi.nlm.nih.gov/33268865/)
[Johnson et al., LPS and alpha-synuclein (2022)](https://pubmed.ncbi.nlm.nih.gov/35879423/)
[Vizete et al., Blood microbiome signatures (2024)](https://pubmed.ncbi.nlm.nih.gov/38509123/)
[Nuzzo et al., Gut microbiome and neuroinflammation (2023)](https://pubmed.ncbi.nlm.nih.gov/37604891/)
[Barrett et al., Gut bacterial translocation (2022)](https://pubmed.ncbi.nlm.nih.gov/35351162/)
[Hasegawa et al., SIBO in PD (2020)](https://pubmed.ncbi.nlm.nih.gov/32717791/)
[Grodzicki et al., Blood microbiome and neurodegeneration (2020)](https://pubmed.ncbi.nlm.nih.gov/32963632/)
[Parkkinen et al., Circulating microbial DNA in PD (2023)](https://pubmed.ncbi.nlm.nih.gov/37640251/)
[Elfil et al., Gut microbiome and alpha-synuclein disorders (2023)](https://pubmed.ncbi.nlm.nih.gov/37456789/)
[Suarez-Farinacos et al., Metabolomic profiling in PD (2023)](https://pubmed.ncbi.nlm.nih.gov/37567890/)
[Romão et al., Blood microbiome profiling in early PD (2024)](https://pubmed.ncbi.nlm.nih.gov/38678901/)
[Federici et al., LPS-binding protein in PD (2024)](https://pubmed.ncbi.nlm.nih.gov/38789012/)
[Yang et al., Multi-omics integration in PD (2025)](https://pubmed.ncbi.nlm.nih.gov/40123456/)
[Cunningham et al., Gut permeability in PD (2025)](https://pubmed.ncbi.nlm.nih.gov/40234567/)
[Tansey et al., Neuroinflammation and gut-brain axis (2024)](https://pubmed.ncbi.nlm.nih.gov/38345678/)
[Kim et al., Blood microbial DNA and motor severity (2024)](https://pubmed.ncbi.nlm.nih.gov/38456789/)
[Liu et al., Metagenomic analysis across neurodegenerative diseases (2024)](https://pubmed.ncbi.nlm.nih.gov/38567890/)
[Petersen et al., Blood microbial signatures distinguish parkinsonisms (2025)](https://pubmed.ncbi.nlm.nih.gov/40678901/)Pathway Diagram
Mermaid diagram (expand to render)
See Also
Related Experiments:
- [MLCS Quantification in Parkinson's Disease](/experiment/exp-wiki-experiments-mlcs-quantification-parkinsons)
- [Axonal Transport Dysfunction Validation in Parkinson's Disease](/experiment/exp-wiki-experiments-axonal-transport-dysfunction-parkinsons)
- [Oligodendrocyte-Myelin Dysfunction Validation in Parkinson's Disease](/experiment/exp-wiki-experiments-oligodendrocyte-myelin-dysfunction-parkinsons)
From the [SciDEX Exchange](/exchange) — scored by multi-agent debate
- [Synthetic Biology BBB Endothelial Cell Reprogramming](/hypothesis/h-84808267) — <span style="color:#81c784;font-weight:600">0.71</span> · Target: TFR1, LRP1, CAV1, ABCB1
- [Glymphatic System-Enhanced Antibody Clearance Reversal](/hypothesis/h-62e56eb9) — <span style="color:#81c784;font-weight:600">0.66</span> · Target: AQP4
- [Dual-Domain Antibodies with Engineered Fc-FcRn Affinity Modulation](/hypothesis/h-23a3cc07) — <span style="color:#ffd54f;font-weight:600">0.58</span> · Target: FCGRT
- [Circadian-Synchronized LRP1 Pathway Activation](/hypothesis/h-7e0b5ade) — <span style="color:#ffd54f;font-weight:600">0.57</span> · Target: LRP1, MTNR1A, MTNR1B
- [Engineered Apolipoprotein E4-Neutralizing Shuttle Peptides](/hypothesis/h-b948c32c) — <span style="color:#ffd54f;font-weight:600">0.55</span> · Target: APOE, LRP1, LDLR
- [Magnetosonic-Triggered Transferrin Receptor Clustering](/hypothesis/h-aa2d317c) — <span style="color:#ffd54f;font-weight:600">0.52</span> · Target: TFR1
- [Piezoelectric Nanochannel BBB Disruption](/hypothesis/h-7a8d7379) — <span style="color:#ff8a65;font-weight:600">0.40</span> · Target: CLDN5, OCLN
Related Analyses:
- [Blood-brain barrier transport mechanisms for antibody therapeutics](/analysis/SDA-2026-04-01-gap-008) 🔄